Clavaseptin 50 mg palatable tablets for dogs and cats

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

Amoxicillin, Clavulanic acid

可用日期:

Vetoquinol UK Limited

ATC代码:

QJ01CR02

INN（国际名称）:

Amoxicillin, Clavulanic acid

剂量:

50 mg/tablet

药物剂型:

Tablet

处方类型:

POM: Prescription Only Medicine as defined in relevant national legislation

治疗组:

Cats, Dogs

治疗领域:

amoxicillin and enzyme inhibitor

疗效迹象:

Antibacterial

授权状态:

Authorised

授权日期:

2005-10-21

产品特点

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clavaseptin 50 mg palatable tablets for dogs and cats
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
Beige scored tablet that can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs and cats.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs:
treatment
or adjunctive treatment
of periodontal
infections caused by bacteria susceptible to amoxicillin in
combination with clavulanic acid i.e._ Pasteurella_ spp.,_
Streptococcus_ spp. and_ Escherichia coli_.
In cats: treatment of skin infections (including wounds and abscesses)
caused by bacteria susceptible to amoxicillin in
combination with clavulanic acid i.e._ Pasteurella_ spp.,_
Staphylococcus_ spp.,_ Streptococcus_ spp. and_ Escherichia coli_.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to penicillins or
other substances of the
-lactam group or to any of
the excipients.
Do not administer to gerbils, guinea pigs, hamsters, rabbits and
chinchillas.
Do not administer to horses and ruminating animals.
Do not use in animals with serious dysfunction of the kidneys
accompanied by anuria or oliguria.
Do not use in cases of known resistance to the combination of
amoxicillin and clavulanic acid.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Each tablet contains:
Active substances:
Amoxicillin (as amoxicillin trihydrate)
40
mg
Clavulanic acid (as potassium salt)
10
mg
Excipients
Brown iron oxide (E172)
0.095 mg
For the full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
__